Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Necati Alp Kılıçaslan, Şermin Börekçi, Gül Nihal Özdemir, Müge Sayitoğlu & Ahmet Emre Eşkazan. (2022) Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?. Expert Review of Respiratory Medicine 16:8, pages 849-852.
Read now
Read now
Shosaku Nomura, Tomoki Ito, Atsushi Satake & Kazuyoshi Ishii. (2019) Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia. Journal of Blood Medicine 10, pages 1-8.
Read now
Read now
Francesco Tarantini, Luisa Anelli, Giuseppe Ingravallo, Immacolata Attolico, Antonella Zagaria, Antonella Russo Rossi, Lucia Lospalluti, Tamara Bufano, Giovanni Zanframundo, Eugenio Maiorano, Giorgina Specchia & Francesco Albano. (2019) Skin lesions in chronic myeloid leukemia patients during dasatinib treatment. Cancer Management and Research 11, pages 7991-7996.
Read now
Read now
Estella Matutes. (2017) Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. Expert Review of Hematology 10:3, pages 251-258.
Read now
Read now
Dilek Keskin, Sevil Sadri & Ahmet Emre Eskazan. (2016) Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Design, Development and Therapy 10, pages 3355-3361.
Read now
Read now
Françoise Huguet. (2015) Dasatinib for acute lymphoblastic leukemia. Expert Opinion on Orphan Drugs 3:11, pages 1339-1356.
Read now
Read now
Articles from other publishers (30)
Maria Agustina Perusini, Igor Novitzky‐Basso, Eshetu G. Atenafu, Donna Forrest, Isabelle Bence‐Bruckler, Lynn Savoie, Mary‐Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy Stockley, Jeffrey H. Lipton, Brian Leber & Dennis Dong Hwan Kim. (2023)
Final report of
TKI
discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (
TRAD
) study
. British Journal of Haematology 203:5, pages 781-791.
Crossref
Crossref
Andrea Rodríguez-Agustín, Víctor Casanova, Judith Grau-Expósito, Sonsoles Sánchez-Palomino, José Alcamí & Núria Climent. (2023) Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging. Pharmaceutics 15:3, pages 917.
Crossref
Crossref
Giuseppe Tridente, Ankit Jana, Arnab Nath & Ghulam Md Ashraf. 2023. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders
403
573
.
Laura Magnano, Andrea Rivero & Estella Matutes. (2022) Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment. Current Oncology Reports 24:5, pages 633-644.
Crossref
Crossref
Maheema Bhaskar, Pavankumar Biraris, Owais Tisekar, Rajiv Kumar Kaushal, Amit Janu & Sandeep Tandon. (2022) Unilateral Interstitial Lung Disease with Contralateral Effusion: Unusual Case Report of Dasatinib Toxicity. Indian Journal of Medical and Paediatric Oncology 43:02, pages 216-222.
Crossref
Crossref
Bruno Fattizzo, Valentina Bellani, Raffaella Pasquale, Juri Alessandro Giannotta & Wilma Barcellini. (2021) Large Granular Lymphocyte Expansion in Myeloid Diseases and Bone Marrow Failure Syndromes: Whoever Seeks Finds. Frontiers in Oncology 11.
Crossref
Crossref
Erin Naismith, Janine Steichen, Sieghart Sopper & Dominik Wolf. (2021) NK Cells in Myeloproliferative Neoplasms (MPN). Cancers 13:17, pages 4400.
Crossref
Crossref
Philippe Rousselot, Luigina Mollica, Joëlle Guilhot, Agnès Guerci, Franck E. Nicolini, Gabriel Etienne, Laurence Legros, Aude Charbonnier, Valérie Coiteux, Caroline Dartigeas, Martine Escoffre‐Barbe, Lydia Roy, Pascale Cony-Makhoul, Viviane Dubruille, Martine Gardembas, Françoise Huguet, Delphine Réa, Emilie Cayssials, François Guilhot, Anne Bergeron, Mathieu Molimard, Francois-Xavier Mahon, Jean-Michel Cayuela, Lambert Busque & Stéphane Bouchet. (2021) Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. British Journal of Haematology 194:2, pages 393-402.
Crossref
Crossref
Claudio Ortolani. 2021. Flow Cytometry of Hematological Malignancies. Flow Cytometry of Hematological Malignancies
301
427
.
Jani-Sofia Almeida, Patrícia Couceiro, Nelson López-Sejas, Vera Alves, Lenka Růžičková, Raquel Tarazona, Rafael Solana, Paulo Freitas-Tavares, Manuel Santos-Rosa & Paulo Rodrigues-Santos. (2019) NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. Frontiers in Immunology 10.
Crossref
Crossref
Núria Climent & Montserrat Plana. (2019) Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection. Frontiers in Pharmacology 10.
Crossref
Crossref
José Rivera-Torres & Esther San José. (2019) Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential. Frontiers in Pharmacology 10.
Crossref
Crossref
Gaetano Alfano, Francesco Fontana, Elisabetta Colaci, Giacomo Mori, Caterina Cerami, Andrea Messerotti, Leonardo Potenza, Mario Luppi & Gianni Cappelli. (2019) T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature. International Journal of Hematology 110:3, pages 313-321.
Crossref
Crossref
Naoki Watanabe, Tomoiku Takaku, Kazuyoshi Takeda, Shuichi Shirane, Tokuko Toyota, Michiaki Koike, Masaaki Noguchi, Takao Hirano, Hiroshi Fujiwara & Norio Komatsu. (2018) Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients. International Journal of Hematology 108:6, pages 588-597.
Crossref
Crossref
Antoine Toubert, Ali Turhan, Agnès Guerci-Bresler, Nicolas Dulphy & Delphine Réa. (2018) Lymphocytes NK : un rôle majeur dans le contrôle immunologique de la leucémie myéloïde chronique. médecine/sciences 34:6-7, pages 540-546.
Crossref
Crossref
Noriyoshi Iriyama, Hiromichi Takahashi, Katsuhiro Miura, Yoshihito Uchino, Masaru Nakagawa, Yoshihiro Hatta & Masami Takei. (2018) Enhanced perforin expression associated with dasatinib therapy in natural killer cells. Leukemia Research 68, pages 1-8.
Crossref
Crossref
Anna Lissina, James E. McLaren, Mette Ilander, Emma I. Andersson, Catherine S. Lewis, Mathew Clement, Andrew Herman, Kristin Ladell, Sian Llewellyn-Lacey, Kelly L. Miners, Emma Gostick, J. Joseph Melenhorst, A. John Barrett, David A. Price, Satu Mustjoki & Linda Wooldridge. (2018) Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions. Scientific Reports 8:1.
Crossref
Crossref
Markus Lindauer & Andreas Hochhaus. 2018. Small Molecules in Hematology. Small Molecules in Hematology
29
68
.
Ryujiro Hara, Makoto Onizuka, Erika Matsusita, Eri Kikkawa, Yoshihiko Nakamura, Hiromichi Matsushita, Daisuke Ohgiya, Hiromichi Murayama, Shinichiro Machida, Ken Ohmachi, Yukari Shirasugi, Yoshiaki Ogawa, Hiroshi Kawada & Kiyoshi Ando. (2017) NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib. International Journal of Hematology 106:5, pages 666-674.
Crossref
Crossref
Amy Hughes & Agnes S. M. Yong. (2017) Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Frontiers in Immunology 8.
Crossref
Crossref
Kazuo Oshimi. (2017) Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias. Internal Medicine 56:14, pages 1759-1769.
Crossref
Crossref
Yoritake Sakoda, Yojiro Arimori, Masakatsu Ueno & Takafumi Matsumoto. (2017) A Suspected Case of an Alveolar Haemorrhage Caused by Dasatinib. Internal Medicine 56:2, pages 203-206.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
221
242
.
Gillian M. Keating. (2016) Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia. Drugs 77:1, pages 85-96.
Crossref
Crossref
Noriyoshi Iriyama, Yoshihiro Hatta & Masami Takei. (2016) Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. Cancer Medicine 5:11, pages 3223-3234.
Crossref
Crossref
Güray Can, Süleyman Ayvaz, Hatice Can, İhsan Karaboğa, Selim Demirtaş, Hasan Akşit, Bülent Yılmaz, Uğur Korkmaz, Mevlüt Kurt & Turan Karaca. (2016) The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis. Clinics and Research in Hepatology and Gastroenterology 40:4, pages 504-516.
Crossref
Crossref
Mohamed El Missiry, Shady Adnan Awad, Hanna L Rajala, Ahmed Al-Samadi, Marja Ekblom, Berit Markevän, Ingbritt Åstrand-Grundström, Maren Wold, Ellen Rabben Svedahl, Birgitte Ravn Juhl, Ole Weis Bjerrum, Inger Haulin, Kimmo Porkka, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen & Satu Mustjoki. (2016) Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. Journal of Cancer Research and Clinical Oncology 142:5, pages 1041-1050.
Crossref
Crossref
Yoshikiyo Ito, Toshihiro Miyamoto, Tomohiko Kamimura, Kenichi Aoki, Hideho Henzan, Takatoshi Aoki, Motoaki Shiratsuchi, Koji Kato, Koji Nagafuji, Ryosuke Ogawa, Tetsuya Eto, Hiromi Iwasaki & Koichi Akashi. (2015) Characteristics of Patients With Development of Large Granular Lymphocyte Expansion Among Dasatinib-Treated Patients With Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia 15:3, pages e47-e54.
Crossref
Crossref
Shunichi Shibazaki, Katsuji Tsuda, Makoto Araki, Misako Yamasaki & Kohei Miura. (2015) A case of long-term survival from chronic myeloid leukemia in a hemodialysis patient receiving imatinib and experiencing cardiotoxicity with dasatinib. Nihon Toseki Igakkai Zasshi 48:12, pages 713-718.
Crossref
Crossref
Ahmet Emre Eskazan, Deniz Eyice, Enes Ali Kurt, Tugrul Elverdi, Fevzi Firat Yalniz, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Burhan Ferhanoglu, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek & Teoman Soysal. (2014) Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leukemia Research 38:7, pages 781-787.
Crossref
Crossref